Urothelial cancer has the third highest rate of HER2 overexpression after breast and gastric cancers, with a wide range from 8.5% to 81% of cases and mutations in and amplifications of HER2 in approximately 6–17% of tumors [141,142]. Here, ERBB2 is linked to gastric cancer.